[
  {
    "ts": null,
    "headline": "Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics",
    "summary": "WALTHAM, Mass., August 06, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization.",
    "url": "https://finnhub.io/api/news?id=264203ba9422a08d4dbea39e9770c23738e5384bfe437fb434db8f85d133c5eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481600,
      "headline": "Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics",
      "id": 136237586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., August 06, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization.",
      "url": "https://finnhub.io/api/news?id=264203ba9422a08d4dbea39e9770c23738e5384bfe437fb434db8f85d133c5eb"
    }
  }
]